Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Boron Compounds
/ administration & dosage
Dexamethasone
/ administration & dosage
Disease-Free Survival
Female
Glycine
/ administration & dosage
Humans
Lenalidomide
/ administration & dosage
Male
Middle Aged
Multiple Myeloma
/ drug therapy
Recurrence
Survival Rate
Ixazomib
Lenalidomide
Myeloma
Real world
Relapsed
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
08
12
2019
accepted:
01
03
2020
pubmed:
3
4
2020
medline:
19
5
2020
entrez:
3
4
2020
Statut:
ppublish
Résumé
Real-world data on regimens for relapsed/refractory multiple myeloma (RRMM) represent an important component of therapeutic decision-making. This multi-centric, retrospective, observational study conducted by the treating physicians evaluated the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in 155 patients who received ixazomib via early access programs in Greece, the UK, and the Czech Republic. Median age was 68 years; 17% had an Eastern Cooperative Oncology Group performance status ≥ 2; median number of prior therapies was 1 (range 1-7); 91%, 47%, and 17% had received prior bortezomib, thalidomide, and lenalidomide, respectively. Median duration of exposure to ixazomib was 9.6 months. Overall response rate was 74%, including 35% very good partial response or better (16% complete response). Median progression-free survival (PFS) was 27.6 months (27.6 and 19.9 months in patients with 1 or > 1 prior lines, respectively). IRd treatment for ≥ 6 months was associated with longer PFS (hazard ratio 0.06). Fourteen patients (9%) discontinued IRd due to adverse events/toxicity in the absence of disease progression. Peripheral neuropathy was reported in 35% of patients (3% grades 3-4). These findings support the results of the phase III TOURMALINE-MM1 trial in a broader real-world RRMM population.
Identifiants
pubmed: 32236735
doi: 10.1007/s00277-020-03981-z
pii: 10.1007/s00277-020-03981-z
doi:
Substances chimiques
Boron Compounds
0
ixazomib
71050168A2
Dexamethasone
7S5I7G3JQL
Lenalidomide
F0P408N6V4
Glycine
TE7660XO1C
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1049-1061Références
Maiese EM, Ainsworth C, Le Moine JG, Ahdesmaki O, Bell J, Hawe E (2018) Comparative efficacy of treatments for previously treated multiple myeloma: a systematic literature review and network meta-analysis. Clin Ther 40(3):480–494 e423. https://doi.org/10.1016/j.clinthera.2018.01.014
doi: 10.1016/j.clinthera.2018.01.014
pubmed: 29500140
Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC (2018) Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia 32(2):252–262. https://doi.org/10.1038/leu.2017.329
doi: 10.1038/leu.2017.329
pubmed: 29257139
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosinol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ, Investigators E (2016) Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17(1):27–38. https://doi.org/10.1016/S1470-2045(15)00464-7
doi: 10.1016/S1470-2045(15)00464-7
pubmed: 26671818
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P, Investigators P (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 375(14):1319–1331. https://doi.org/10.1056/NEJMoa1607751
doi: 10.1056/NEJMoa1607751
pubmed: 27705267
Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, Weisel KC, Oriol A, Hansson M, Vacca A, Blanchard MJ, Goldschmidt H, Doyen C, Kaiser M, Petrini M, Anttila P, Cafro AM, Raymakers R, San-Miguel J, de Arriba F, Knop S, Rollig C, Ocio EM, Morgan G, Miller N, Simcock M, Peluso T, Herring J, Sternas L, Zaki MH, Moreau P (2016) Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood 128(4):497–503. https://doi.org/10.1182/blood-2016-02-700872
doi: 10.1182/blood-2016-02-700872
pubmed: 27226434
pmcid: 5009959
Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Rollig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P, Investigators E (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373(7):621–631. https://doi.org/10.1056/NEJMoa1505654
doi: 10.1056/NEJMoa1505654
pubmed: 26035255
Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG, Group T-MS (2016) Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 374(17):1621–1634. https://doi.org/10.1056/NEJMoa1516282
doi: 10.1056/NEJMoa1516282
pubmed: 27119237
Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P, Investigators C (2016) Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 375(8):754–766. https://doi.org/10.1056/NEJMoa1606038
doi: 10.1056/NEJMoa1606038
pubmed: 27557302
Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF (2016) Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood 127(6):713–721. https://doi.org/10.1182/blood-2015-09-665018
doi: 10.1182/blood-2015-09-665018
pubmed: 26631116
pmcid: 4760132
Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A, Investigators A (2015) Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372(2):142–152. https://doi.org/10.1056/NEJMoa1411321
doi: 10.1056/NEJMoa1411321
pubmed: 25482145
Bergin K, McQuilten Z, Moore E, Wood E, Spencer A (2017) Myeloma in the real world: what is really happening? Clin Lymphoma Myeloma Leuk 17(3):133–144 e131. https://doi.org/10.1016/j.clml.2016.12.002
doi: 10.1016/j.clml.2016.12.002
pubmed: 28153487
Blimark CH, Turesson I, Genell A, Ahlberg L, Bjorkstrand B, Carlson K, Forsberg K, Juliusson G, Linder O, Mellqvist UH, Nahi H, Kristinsson SY, Swedish Myeloma R (2018) Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish myeloma registry. Haematologica 103(3):506–513. https://doi.org/10.3324/haematol.2017.178103
doi: 10.3324/haematol.2017.178103
pubmed: 29217784
pmcid: 5830385
Chen CC, Parikh K, Abouzaid S, Purnomo L, McGuiness CB, Hussein M, Wade RL (2017) Real-world treatment patterns, time to next treatment, and economic outcomes in relapsed or refractory multiple myeloma patients treated with pomalidomide or carfilzomib. J Manag Care Spec Pharm 23(2):236–246. https://doi.org/10.18553/jmcp.2017.23.2.236
doi: 10.18553/jmcp.2017.23.2.236
pubmed: 28125372
Hajek R, Jarkovsky J, Maisnar V, Pour L, Spicka I, Minarik J, Gregora E, Kessler P, Sykora M, Frankova H, Campioni M, DeCosta L, Treur M, Gonzalez-McQuire S, Bouwmeester W (2018) Real-world outcomes of multiple myeloma: retrospective analysis of the Czech registry of monoclonal gammopathies. Clin Lymphoma Myeloma Leuk 18(6):e219–e240. https://doi.org/10.1016/j.clml.2018.04.003
doi: 10.1016/j.clml.2018.04.003
pubmed: 29793653
Jagannath S, Abonour R, Durie BGM, Gasparetto C, Hardin JW, Narang M, Terebelo HR, Toomey K, Wagner L, Srinivasan S, Kitali A, Yue L, Flick ED, Agarwal A, Rifkin RM (2018) Heterogeneity of second-line treatment for patients with multiple myeloma in the connect MM registry (2010-2016). Clin Lymphoma Myeloma Leuk 18(7):480–485 e483. https://doi.org/10.1016/j.clml.2018.04.007
doi: 10.1016/j.clml.2018.04.007
pubmed: 29844008
Jagannath S, Roy A, Kish J, Lunacsek O, Globe D, Eaddy M, Kuriakose ET, Willey J, Butler-Bird S, Siegel D (2016) Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices. Expert Rev Hematol 9(7):707–717. https://doi.org/10.1080/17474086.2016.1195254
doi: 10.1080/17474086.2016.1195254
pubmed: 27291638
Knauf W, Aldaoud A, Hutzschenreuter U, Klausmann M, Dille S, Wetzel N, Janicke M, Marschner N, the TLN-Group (Tumour Registry Lymphatic Neoplasms) (2018) Survival of non-transplant patients with multiple myeloma in routine care differs from that in clinical trials-data from the prospective German tumour registry lymphatic neoplasms. Ann Hematol 97(12):2437–2445. https://doi.org/10.1007/s00277-018-3449-8
doi: 10.1007/s00277-018-3449-8
pubmed: 30069704
pmcid: 6208687
Orlowski RZ (2018) Letter—incorporating real-world evidence and patient value criteria into value-based frameworks for relapsed/refractory multiple myeloma. J Manag Care Spec Pharm 24(5):487. https://doi.org/10.18553/jmcp.2018.24.5.487
doi: 10.18553/jmcp.2018.24.5.487
pubmed: 29694283
Raab MS, Cavo M, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos MV, Schoen P, Yong K (2016) Multiple myeloma: practice patterns across Europe. Br J Haematol 175(1):66–76. https://doi.org/10.1111/bjh.14193
doi: 10.1111/bjh.14193
pubmed: 27291397
Shah JJ, Abonour R, Gasparetto C, Hardin JW, Toomey K, Narang M, Srinivasan S, Kitali A, Zafar F, Flick ED, Rifkin RM (2017) Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes. Clin Lymphoma Myeloma Leuk 17(9):575–583 e572. https://doi.org/10.1016/j.clml.2017.06.013
doi: 10.1016/j.clml.2017.06.013
pubmed: 28886839
Terpos E, Suzan F, Goldschmidt H (2018) Going the distance: are we losing patients along the multiple myeloma treatment pathway? Crit Rev Oncol Hematol 126:19–23. https://doi.org/10.1016/j.critrevonc.2018.03.021
doi: 10.1016/j.critrevonc.2018.03.021
pubmed: 29759561
Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, Safaei R, Karlin L, Mateos MV, Raab MS, Schoen P, Cavo M (2016) Multiple myeloma: patient outcomes in real-world practice. Br J Haematol 175(2):252–264. https://doi.org/10.1111/bjh.14213
doi: 10.1111/bjh.14213
pubmed: 27411022
pmcid: 5096152
Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, Palumbo A, Luptakova K, Romanus D, Skacel T, Kumar SK, Anderson KC (2018) Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J 8(11):109. https://doi.org/10.1038/s41408-018-0141-0
doi: 10.1038/s41408-018-0141-0
pubmed: 30413684
pmcid: 6226527
Gupta N, Hanley MJ, Xia C, Labotka R, Harvey RD, Venkatakrishnan K (2019) Clinical pharmacology of Ixazomib: the first oral proteasome inhibitor. Clin Pharmacokinet 58(4):431–449. https://doi.org/10.1007/s40262-018-0702-1
doi: 10.1007/s40262-018-0702-1
pubmed: 30117017
Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blade J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016) International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328–e346. https://doi.org/10.1016/S1470-2045(16)30206-6
doi: 10.1016/S1470-2045(16)30206-6
Hajek R, Terpos E, Lee HC, Chari A, Costello CL, Puig N, Leleu X, Berdeja JG, Davies FE, Weisel K, Usmani SZ, Hungria VTM, Boccadoro M, Rifkin RM, Zonder JA, Cook G, Brožová L, Bařinová M, Ren K, Cacioppo R, Skacel T, Stull DM, Maisnar V (2018) Ixazomib plusl-dexamethasone (IRd) in relapsed/refractory multiple myeloma (MM) patients (Pts)–effectiveness in routine clinical practice is similar to the efficacy in the phase 3 tourmaline-MM1 trial: a pooled analysis from the insight MM observational study and the Czech registry of monoclonal gammopathies (RMG). Blood 132(Suppl 1):1971
doi: 10.1182/blood-2018-99-113441
Ziff M, Cheesman S, Kyriakou C, Mehta A, Papanikolaou X, Rabin N, Wechalekar A, Yong K, Popat R (2017) Real world use of ixazomib with lenalidomide and dexamethasone for patients with relapsed and relapsed refractory multiple myeloma. Haematologica 102(s2):786–787
Mateos MV, Masszi T, Grzasko N, Hansson M, Sandhu I, Pour L, Viterbo L, Jackson SR, Stoppa AM, Gimsing P, Hamadani M, Borsaru G, Berg D, Lin J, Di Bacco A, van de Velde H, Richardson PG, Moreau P (2017) Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. Haematologica 102(10):1767–1775. https://doi.org/10.3324/haematol.2017.170118
doi: 10.3324/haematol.2017.170118
pubmed: 28751562
pmcid: 5622861
Boccadoro M, Usmani SZ, Chari A, Rifkin R, Abonour R, Berdeja J, Cook G, Costello C, Goldschmidt H, Hajek R, Hungria V, Lee HC, Leleu X, Omel J, Spencer A, Thompson MA, Vela-Ojeda J, Zonder JA, Puig N, Aguarón A, Davies FE, Demers B, Ren K, Yu S, Skacel T, Stull DM, Terpos E (2018) A global treatment standard in multiple myeloma (MM) remains elusive despite advances in care over 15 years: first results from INSIGHT MM, the largest global prospective, observational MM study. Hemasphere 2(s1):591
Vij R, Khare S, Perez S, Popov S, Chen C (2016) Subgroup analysis of US patients in preamble, an ongoing multinational observational study in multiple myeloma. Blood 128(22):2362
doi: 10.1182/blood.V128.22.2362.2362
Kuter D, Cook G, Goldschmidt H, Cella D, Zyczynski T, Davis C, Popov S, Vij R (2016) An ongoing multinational observational study in multiple myeloma (PREAMBLE): preliminary report on progression-free survival. Haematologica 101(s1):520
Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, Bekadja MA, Legiec W, Dimopoulos M, Stankovic S, Duran MS, De Stefano V, Corso A, Kochkareva Y, Laane E, Berthou C, Salwender H, Masliak Z, Peceliunas V, Willenbacher W, Silva J, Louw V, Nemet D, Borbenyi Z, Abadi U, Pedersen RS, Cernelc P, Potamianou A, Couturier C, Feys C, Thoret-Bauchet F, Boccadoro M, Investigators E (2018) Multiple myeloma treatment in real-world clinical practice: results of a prospective, multinational, noninterventional study. Clin Lymphoma Myeloma Leuk 18(10):e401–e419. https://doi.org/10.1016/j.clml.2018.06.018
doi: 10.1016/j.clml.2018.06.018
pubmed: 30030033
Hari P, Romanus D, Luptakova K, Blazer M, Yong C, Raju A, Farrelly E, Labotka R, Morrison VA (2018) The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapies. J Geriatr Oncol 9(2):138–144. https://doi.org/10.1016/j.jgo.2017.09.007
doi: 10.1016/j.jgo.2017.09.007
pubmed: 29056336
Minarik J, Hajek R, Jungova A, Mistrik M, Pika T, Gregora E, Radocha J, Straub J, Pour L, Wrobel M, Brozova L, Bacovsky J, Krhovska P, Hradska K, Jindra P, Pavlicek P, Machalkova K, Spicka I, Stork M, Jelinek T, Plonkova H, Scudla V, Maisnar V (2018) Ixazomib, lenalidomide and dexamethasone for relapsed and refractory multiple myeloma - data from the Czech registry of monoclonal gammopathies. Hemasphere 2(S1):247
Varga G, Nagy Z, Demeter J, Kosztolanyi S, Szomor A, Alizadeh H, Deak B, Schneider T, Plander M, Szendrei T, Varoczy L, Illes A, Batai A, Peto M, Mikala G (2019) Real world efficacy and safety results of ixazomib lenalidomide and dexamethasone combination in relapsed/refractory multiple myeloma: data collected from the Hungarian ixazomib named patient program. Pathol Oncol Res 25:1615–1620. https://doi.org/10.1007/s12253-019-00607-2
doi: 10.1007/s12253-019-00607-2
pubmed: 30712192
pmcid: 6815275
Kumar S, Moreau P, Hari P, Mateos MV, Ludwig H, Shustik C, Masszi T, Spencer A, Hajek R, Romeril K, Avivi I, Liberati AM, Minnema MC, Einsele H, Lonial S, Berg D, Lin J, Gupta N, Esseltine DL, Richardson PG (2017) Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. Br J Haematol 178(4):571–582. https://doi.org/10.1111/bjh.14733
doi: 10.1111/bjh.14733
pubmed: 28485007
pmcid: 5574012
Chari A, Romanus D, Farrelly E, Huang H, Blazer M, Raju A, Noga S, Richardson P (2018) Randomized clinical trial (RCT) representativeness & outcomes in relapsed/refractory multiple myeloma (RRMM) real world (RW) patients: comparison of ASPIRE, TOURMALINE-MM1, POLLUX, & ELOQUENT RCTs. Hemasphere 2(S1):610
Schmitz S, Maguire A, Morris J, Ruggeri K, Haller E, Kuhn I, Leahy J, Homer N, Khan A, Bowden J, Buchanan V, O'Dwyer M, Cook G, Walsh C (2018) The use of single armed observational data to closing the gap in otherwise disconnected evidence networks: a network meta-analysis in multiple myeloma. BMC Med Res Methodol 18(1):66. https://doi.org/10.1186/s12874-018-0509-7
doi: 10.1186/s12874-018-0509-7
pubmed: 29954322
pmcid: 6022299
van Beurden-Tan CHY, Franken MG, Blommestein HM, Uyl-de Groot CA, Sonneveld P (2017) Systematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple myeloma. J Clin Oncol 35(12):1312–1319. https://doi.org/10.1200/JCO.2016.71.1663
doi: 10.1200/JCO.2016.71.1663
pubmed: 28240968
Bringhen S, Milan A, Ferri C, Wasch R, Gay F, Larocca A, Salvini M, Terpos E, Goldschmidt H, Cavo M, Petrucci MT, Ludwig H, Auner HW, Caers J, Gramatzki M, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M, European Hematology Association tEMN, the Italian Society of Arterial H (2018) Cardiovascular adverse events in modern myeloma therapy-incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). Haematologica 103(9):1422–1432. https://doi.org/10.3324/haematol.2018.191288
doi: 10.3324/haematol.2018.191288
pubmed: 30049825
pmcid: 6119131